According to filings with the U.S. Securities and Exchange Commission, Phase Genomics is raising $6,579,358.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Ivan Liachko played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Phase Genomics
Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.

To learn more about Phase Genomics, visit http://phasegenomics.com/

Contact:
Ivan Liachko, Chief Executive Officer
206-384-6228

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.